Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis
Blood Cancer Journal, Published online: 22 March 2024; doi:10.1038/s41408-024-01034-6Once-weekly versus twice-weekly bortezomib in newly diagnosed multiple myeloma: a real-world analysis (Source: Blood Cancer Journal)
Source: Blood Cancer Journal - March 22, 2024 Category: Hematology Authors: Fieke W. Hoff Rahul Banerjee Adeel M. Khan Georgia McCaughan Bo Wang Xiaoliang Wang James Roose Larry D. Anderson Jr. Andrew J. Cowan S. Vincent Rajkumar Gurbakhash Kaur Source Type: research
Survival Analysis of Newly Diagnosed Multiple Myeloma Patients after Frontline Autologous Stem Cell Transplantation in a Real-Life Setting
CONCLUSION: ASCT is a feasible, safe, and potent strategy that provides a prolonged median OS and PFS in NDMM patients. This approach can be implemented in low-income countries.PMID:38511422 | DOI:10.14712/18059694.2024.4 (Source: Acta Medica: Hradec Kralove)
Source: Acta Medica: Hradec Kralove - March 21, 2024 Category: General Medicine Authors: David Garrido Virginia Bove Fiorella Villano Elo ísa Riva Source Type: research
